Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) has announced the commencement of a groundbreaking triple immunotherapy combination study with the dosing of the first patient. This pioneering clinical-stage cancer immunotherapy study is testing the efficacy of combining COM701, Compugen’s potential first-in-class anti-PVRIG antibody, COM902, Compugen’s potential best-in-class anti-TIGIT antibody, and pembrolizumab to treat patients with platinum-resistant ovarian cancer.
We are thrilled to announce that the first patient with platinum-resistant ovarian cancer has been given Compugen’s pioneering triple immunotherapy combination of COM701, COM902, and pembrolizumab in our proof-of-concept study. Our goal with this study is to build on the encouraging results reported at the ESMO Immuno-Oncology Congress 2022 and develop a deeper understanding of all the components involved, in order to better identify the patients most likely to respond. We look forward to the initial study findings before the end of this year, as we pave the way for a potential registration.
Dr. Manish Sharma, Associate Director of Clinical Research at START Midwest in Grand Rapids, Michigan, is thrilled to take part in the proof-of-concept study on the triple immunotherapy combination of COM701, COM902 and pembrolizumab to address the unmet need for treatments for patients with platinum resistant ovarian cancer.
So far, this combination has been found to be well-tolerated, according to their recent microsatellite stable colorectal cancer proof-of-concept study. By targeting DNAM-1, PVRIG, TIGIT and PD-1 pathways, this novel therapy could provide additional treatment options for those suffering from this condition.
Details on the study:
This proof-of-concept study (NCT04354246) is an open label initiative, offering a new hope to up to 40 patients with advanced ovarian cancer, including those with fallopian tube cancer and primary peritoneal cancer who have received up to three prior lines of therapy. Featuring a combination of the novel therapies COM701 and COM902 alongside the established immunotherapy pembrolizumab, the study comes following promising results at ESMO-IO 2022 that showcased a favorable safety and tolerability profile along with a durable anti-tumor response. All histologies are eligible to join this exciting new trial, offering renewed hope in our fight against ovarian cancer!
About Compugen
Compugen is an innovative clinical-stage therapeutic discovery and development company utilizing the power of predictive computational capabilities to discover cutting-edge cancer immunotherapies. Two of their proprietary product candidates, COM701 and COM902, are paving the way for potentially groundbreaking therapies.
Their partnered program with AstraZeneca, rilvegostomig, is currently in Phase 2 clinical trials, and their pipeline of early-stage immuno-oncology programs include COM503 which is currently undergoing IND enabling studies. Based in Israel with an office in San Francisco, Compugen’s shares can be found on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Forward-Looking Statement
Compugen is pioneering a new breakthrough in the pursuit to understand and treat ovarian cancer. Through the use of a differentiated approach to block three pathways in the DNAM-1 axis, PVRIG, TIGIT and PD-1, our team is hopeful that this will result in additional treatment options for those with platinum resistant ovarian cancer.
We expect to report initial findings by the end of 2023 in order to better understand the contribution of the components that will contribute to our biomarker work. However, this endeavor is uncertain and involves a lengthy and expensive process with a number of risks that must be considered.